Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

Joseph A. Lewnard, Vennis X. Hong, Manish M. Patel, Rebecca Kahn, Marc Lipsitch, Sara Y. Tartof
doi: https://doi.org/10.1101/2022.01.11.22269045
Joseph A. Lewnard
1Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
2Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
3Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jLewnard@berkeley.edu Sara.Y.Tartof@kp.org
Vennis X. Hong
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish M. Patel
5COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, 30329, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Kahn
5COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, 30329, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lipsitch
5COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, 30329, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Y. Tartof
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
6Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jLewnard@berkeley.edu Sara.Y.Tartof@kp.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by December 2021. Risk of severe outcomes associated with Omicron infections, as compared to earlier SARS-CoV-2 variants, remains unclear.

Methods We analyzed clinical and epidemiologic data from cases testing positive for SARS-CoV-2 infection within the Kaiser Permanente Southern California healthcare system from November 30, 2021 to January 1, 2022, using S gene target failure (SGTF) as assessed by the ThermoFisher TaqPath ComboKit assay as a proxy for Omicron infection. We fit Cox proportional hazards models to compare time to any hospital admission and hospital admissions associated with new-onset respiratory symptoms, intensive care unit (ICU) admission, mechanical ventilation, and mortality among cases with Omicron and Delta (non-SGTF) variant infections. We fit parametric competing risk models to compare lengths of hospital stay among admitted cases with Omicron and Delta variant infections.

Results Our analyses included 52,297 cases with SGTF (Omicron) and 16,982 cases with non-SGTF (Delta [B.1.617.2]) infections, respectively. Hospital admissions occurred among 235 (0.5%) and 222 (1.3%) of cases with Omicron and Delta variant infections, respectively. Among cases first tested in outpatient settings, the adjusted hazard ratios for any subsequent hospital admission and symptomatic hospital admission associated with Omicron variant infection were 0.48 (0.36-0.64) and 0.47 (0.35-0.62), respectively. Rates of ICU admission and mortality after an outpatient positive test were 0.26 (0.10-0.73) and 0.09 (0.01-0.75) fold as high among cases with Omicron variant infection as compared to cases with Delta variant infection. Zero cases with Omicron variant infection received mechanical ventilation, as compared to 11 cases with Delta variant infections throughout the period of follow-up (two-sided p<0.001). Median duration of hospital stay was 3.4 (2.8-4.1) days shorter for hospitalized cases with Omicron variant infections as compared to hospitalized patients with Delta variant infections, reflecting a 69.6% (64.0-74.5%) reduction in hospital length of stay.

Conclusions During a period with mixed Delta and Omicron variant circulation, SARS-CoV-2 infections with presumed Omicron variant infection were associated with substantially reduced risk of severe clinical endpoints and shorter durations of hospital stay.

Trial registration Not applicable

Competing Interest Statement

JAL discloses receipt of grants from Pfizer and Merck, Sharp & Dohme, and consulting fees from Pfizer, Merck, Sharp & Dohme, and VaxCyte, Inc., unrelated to this work. SYT discloses receipt of grants from Pfizer unrelated to this work. ML reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer, personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside the submitted work; and Unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, Covaxx (United Biomedical). VXH, MMP, and RK have no competing interests to disclose.

Funding Statement

The study was funded by the US Centers for Disease Control and Prevention.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was reviewed and approved by the Kaiser Permanente Southern California Institutional Review Board, which waived requirement for informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.

Data Availability

Requests for access to data should be submitted to Sara.Y.Tartof{at}kp.org.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 11, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
Joseph A. Lewnard, Vennis X. Hong, Manish M. Patel, Rebecca Kahn, Marc Lipsitch, Sara Y. Tartof
medRxiv 2022.01.11.22269045; doi: https://doi.org/10.1101/2022.01.11.22269045
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
Joseph A. Lewnard, Vennis X. Hong, Manish M. Patel, Rebecca Kahn, Marc Lipsitch, Sara Y. Tartof
medRxiv 2022.01.11.22269045; doi: https://doi.org/10.1101/2022.01.11.22269045

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9759)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2304)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1554)
  • Health Policy (733)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11635)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2140)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2173)
  • Public and Global Health (4649)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)